Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/201304
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | CIBER-CLAP (CIBERCV Cardioprotection Large Animal Platform): A multicenter preclinical network for testing reproducibility in cardiovascular interventions |
Autor: | Roselló, Xavier; Rodríguez-Sinovas, Antonio; Vilahur, Gemma CSIC ORCID; Crisostomo, Veronica; Jorge, Inmaculada CSIC ORCID; Zaragoza, Carlos; Zamorano, José L.; Bermejo, Javier; Ordóñez Fernández, Antonio CSIC ORCID; Boscá, Lisardo CSIC ORCID CVN ; Vázquez, Jesús CSIC ORCID CVN; Badimón Maestro, Lina CSIC ORCID; Sánchez-Margallo, Francisco M.; Fernández-Avilés, Francisco; García-Dorado, David; Ibanez, Borja | Fecha de publicación: | 30-dic-2019 | Editor: | Springer Nature | Citación: | Scientific Reports 9: 20290 (2019) | Resumen: | Despite many cardioprotective interventions have shown to protect the heart against ischemia/reperfusion injury in the experimental setting, only few of them have succeeded in translating their findings into positive proof-of-concept clinical trials. Controversial and inconsistent experimental and clinical evidence supports the urgency of a disruptive paradigm shift for testing cardioprotective therapies. There is a need to evaluate experimental reproducibility before stepping into the clinical arena. The CIBERCV (acronym for Spanish network-center for cardiovascular biomedical research) has set up the “Cardioprotection Large Animal Platform” (CIBER-CLAP) to perform experimental studies testing the efficacy and reproducibility of promising cardioprotective interventions based on a pre-specified design and protocols, randomization, blinding assessment and other robust methodological features. Our first randomized, control-group, open-label blinded endpoint experimental trial assessing local ischemic preconditioning (IPC) in a pig model of acute myocardial infarction (n = 87) will be carried out in three separate sets of experiments performed in parallel by three laboratories. Each set aims to assess: (A) CMR-based outcomes; (B) histopathological-based outcomes; and (C) protein-based outcomes. Three core labs will assess outcomes in a blinded fashion (CMR imaging, histopathology and proteomics) and 2 methodological core labs will conduct the randomization and statistical analysis. | Versión del editor: | https://doi.org/10.1038/s41598-019-56613-6 | URI: | http://hdl.handle.net/10261/201304 | DOI: | 10.1038/s41598-019-56613-6 | E-ISSN: | 2045-2322 |
Aparece en las colecciones: | (IBIS) Artículos (IIBM) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
s41598-019-56613-6.pdf | 1,52 MB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
10
checked on 14-abr-2024
SCOPUSTM
Citations
14
checked on 19-abr-2024
WEB OF SCIENCETM
Citations
13
checked on 23-feb-2024
Page view(s)
186
checked on 24-abr-2024
Download(s)
168
checked on 24-abr-2024